Case Series

Two Chronic Myeloid Leukemia Patients Presenting with Isolated Thrombocytosis

Mehmet Hilmi DOGU 1, Istemi SERIN 1, Elif SUYANI 2

1University of Health Sciences, Istanbul Training and Research Hospital, Department of Hematology Istanbul
2University of Health Sciences, Adana Training and Research Hospital, Department of Hematology Istanbul

Corresponding author: Istemi SERIN, MD; serinistemi@hotmail.com

Received 22 July 2020; Accepted 13 August 2020; Published 20 August 2020

Abstract

Chronic myeloid leukemia (CML) usually present with high leukocyte counts and splenomegaly and isolated thrombocytosis is not a common condition in CML. We present two CML patients presenting with isolated thrombocytosis. Case 1: A 44-year-old male patient having isolated thrombocytosis with no additional features, was investigated with the suspicion of essential thrombocythemia (ET). However, he was found to be positive for BCR/ABL. Afterwords, imatinib with the dosage of 400 mg/day was started and a major molecular response was obtained. Case 2: A 74-year-old woman was referred to our outpatient clinic because of thrombocytosis. Her physical examination was normal without splenomegaly. Further investigations were planned with the suspicion of ET, but the patient’s BCR/ABL was positive. She was started imatinib and a major molecular response was obtained. In these cases, we explored the presence of BCR/ABL and found that they were positive. In conclusion, screening for BCR/ABL has a substantial significance in patients with isolated thrombocytosis and not exhibiting CML findings, to provide an effective therapeutic approach for these patients.

Keywords: CML, Ph Chromosome, BCR / ABL, Thrombocytosis, Imatinib

Introduction

Chronic myeloid leukemia (CML), which is a clonal stem cell disease, usually presents with splenomegaly and high leukocyte counts caused by mature myeloid hyperplasia in the bone marrow. Philadelphia chromosome (Ph), generated by the t(9;22), is detected by cytogenetic examination in CML patients. This translocation leads to the fusion of the Abelson oncogene (ABL) from chromosome 9q34 with the breakpoint cluster region (BCR) on chromosome 22q11.2, t(9;22)(q34;q11.2) and actually produces BCR/ABL oncogene [1].

Essential thrombocythemia (ET) is also a clonal bone marrow disease in the group of BCR/ABL negative chronic myeloproliferative diseases (CMPDs). In about half of ET patients, the janus kinase (JAK) 2V617F mutation is detected and a minority of the patients have calreticulin (CALR), myeloproliferative leukemia virus oncogene (MPL) and other mutations. While thrombocytosis is the prominent feature of ET [2], it is not a common condition in CML.

Here, we present two CML patients presenting with isolated thrombocytosis.

Cases

Our first case was a 44-year-old male patient. During his routine control, his blood count was found to be as follows: White blood cell (WBC): 4.86 x 10^9/L, neutrophil: 3.47 x10^9/L, hemoglobin: 14 g/ dL, platelet: 1,189 x10^9/L. His physical examination revealed no remarkable findings. Further investigations were planned with the doubt of ET. However, he was found to be positive for Ph chromosome after the cytogenetic examination of the bone marrow. Afterwards, imatinib with the dosage of 400 mg/day was started and a major molecular response was obtained.

Our second case was a 74-year-old woman. She was referred to our outpatient clinic because of thrombocytosis. Her physical examination was normal without splenomegaly. The complete blood count was as follows: WBC: 9.18 10^9/L, neutrophil: 5.47 10^9/L, hemoglobin: 11.5 g/ dL and platelet: 1,822 x10^9/L. Further investigations were planned with the doubt of ET. She was given hydroxyurea till the cytogenetic and molecular results were obtained. The patient’s BCR/ABL was positive, thus hydroxyurea was ceased and imatinib was started with a dosage of 400 mg. Due to the cytopenia under imatinib 400 mg/day, the dosage of was declined to 300 mg and a major molecular response was obtained with imatinib 300 mg/day treatment.

Discussion

Chronic myeloproliferative diseases are conventionally categorized as BCR/ABL positive and BCR/ABL negative CMPDs [3]. While BCR/ABL negative CMPDs include polycythemia vera (PV), primary myelofibrosis (PMF) and ET, CML is the only member of...
BCR/ABL positive CMPD [3]. Although ET is among the BCR/ABL negative CMPD group, Michielis et al. introduced a term called as Ph (+) ET which is characterized by increased small mononuclear megakaryocytes in the bone marrow smears and biopsies, in addition to thrombocytosis. Besides, there is no finding of CML regarding the peripheral blood smear and physical examination in Ph (+) positive ET patients. Moreover, microvascular or hemorrhagic complications are not observed in those patients different from both classical ET and CML [3,30].

Differently, the World Health Organization (WHO) assumes the BCR/ABL positive isolated thrombocytosis as CML, not ET [11]. This classification is concordant with Hannover Bone Marrow Classification who divided BCR/ABL positive CML into three separate groups as; CML- common type (CML-CT), CML-megakaryocyte-increased (CML-MI) and CML-megakaryocyte predominant (CML-MP) [11]. And BCR/ABL positive ET can be defined as a CML subtype as CML-MP. This classification seems to be more appropriate considering that the patients with isolated thrombocytosis and BCR/ABL positivity should be treated with tyrosine kinase inhibitors (TKIs). According to the WHO classification, exclusion of other myeloid neoplasms is mandatory for the diagnosis of ET [12]. Therefore, search for BCR/ABL is required in ET patients [12]. And our cases emphasize the significance of this criteria.

In these cases, we explored the presence of BCR/ABL and found that they were positive. Hence, they were treated with a TKI instead of hydroxyurea and major molecular response was obtained in two patients in the early period. Certainly, screening for BCR/ABL should not be omitted in patients with isolated thrombocytosis and not exhibiting CML findings such as splenomegaly and leukocytosis, to provide an effective therapeutic approach for these patients.

Abbreviations

CML: Chronic Myeloid Leukemia
ET: Essential Thrombocythaemia
Ph: Philadelphia Chromosome
BCR: Breakpoint Cluster Region
ABL: Abelson Oncogene
CMPD: Chronic Myeloproliferative Diseases
JAK: Janus Kinase
MPL: Myeloproliferative Leukemia Virus Oncogene
CALR: Calreticulin
WBC: White Blood Cell
PV: Polycythemia Vera
PMF: Primary Myelofibrosis
CML-CT: CML- Common Type
CML-MI: CML-Megakaryocyte-Increased
CML-MP: CML-Megakaryocyte Predominant
TKI: Tyrosine Kinase Inhibitors

Competing Interests

The authors declare that they have no competing interests.

Funding

No funding was received. None of the authors has disclosures relevant to this manuscript.

Author Contributions

All authors contributed to the editing of the manuscript. IS wrote the manuscript and made the accompanying pictures.

Acknowledgements

We respectfully remember all the colleagues we lost in the COVID-19 fight.

References

[1] Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020 Apr;34(4):966-984. doi: 10.1038/s41375-020-0776-2.
[2] Tefferi, A., Vannucchi, A.M. & Barbui, T. Essential thrombocythemia treatment algorithm 2018. Blood Cancer Journal 8, 2 (2018). https://doi.org/10.1038/s41408-017-0041-83.
[3] Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer. 2009 Sep 1;115(17):3842-7. doi: 10.1002/cncr.24440.
[4] Tefferi A, Pardanani A. Myeloproliferative Neoplasms: A Contemporary Review. JAMA Oncol. 2015 Apr;1(1):97-105. doi: 10.1001/jamaoncol.2015.89.
[5] Landibluom AR, Bower H, Andersson TM, Dickman PW, Samuelsson J, Björkholm M et al. Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients. Leukemia. 2018 Oct;32(10):2203-2210. doi: 10.1038/s41375-018-0027-y.
[6] Hassankanishnamurthy S, Mody MD, Kota VK. A Case of Chronic Myelogenous Leukemia Occurring in a Patient Treated for Essential Thrombocythemia. Am J Case Rep. 2019 Jan 3;20:10-14. doi: 10.12659/AJCR.911854.
[7] Murphy S, Peterson P, Ilidan H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol. 1997 Jan;34(1):29-39.
[8] Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999 Dec;17(12):3835-49. doi: 10.1200/JCO.1999.17.12.3835.
[9] Michielis JJ, Berneman Z, Schroyens W, Kutti J, Swoln B, Ridell B et al. Philadelphia (Ph) chromosome-positive thrombocythemia without features of chronic myeloid
leukemia in peripheral blood: natural history and diagnostic differentiation from Ph-negative essential thrombocytethemia. Ann Hematol. 2004 Aug;83(8):504-12. doi: 10.1007/s00277-004-0877-4.

[10] Fadilah SA, Cheong SK. BCR-ABL positive essential thrombocythaemia: a variant of chronic myelogeuerous leukaemia or a distinct clinical entity: a special case report. Singapore Med J. 2000 Dec;41(12):595-8.

[11] Georgii A, Vykoupil KF, Buhr T, Choritz H, Döhler U, Kaloutsi V et al. Chronic myeloproliferative disorders in bone marrow biopsies. Pathol Res Pract. 1990 Feb;186(1):3-27. doi: 10.1016/S0344-0338(11)81008-3.

[12] Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018 Feb 9;8(2):15. doi: 10.1038/s41408-018-0054-y.